Your browser doesn't support javascript.
loading
Clonal evolution in myeloma: the impact of maintenance lenalidomide and depth of response on the genetics and sub-clonal structure of relapsed disease in uniformly treated newly diagnosed patients.
Jones, John R; Weinhold, Niels; Ashby, Cody; Walker, Brian A; Wardell, Chris; Pawlyn, Charlotte; Rasche, Leo; Melchor, Lorenzo; Cairns, David A; Gregory, Walter M; Johnson, David; Begum, Dil B; Ellis, Sidra; Sherborne, Amy L; Cook, Gordon; Kaiser, Martin F; Drayson, Mark T; Owen, Roger G; Jackson, Graham H; Davies, Faith E; Greaves, Mel; Morgan, Gareth J.
Afiliación
  • Jones JR; Department of Haematology, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • Weinhold N; The Institute of Cancer Research, London, UK.
  • Ashby C; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Walker BA; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Wardell C; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Pawlyn C; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Rasche L; Department of Haematology, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • Melchor L; The Institute of Cancer Research, London, UK.
  • Cairns DA; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Gregory WM; The Institute of Cancer Research, London, UK.
  • Johnson D; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, UK.
  • Begum DB; Clinical Trials Research Unit, Leeds Institute of Clinical Trials Research, University of Leeds, UK.
  • Ellis S; The Institute of Cancer Research, London, UK.
  • Sherborne AL; The Institute of Cancer Research, London, UK.
  • Cook G; The Institute of Cancer Research, London, UK.
  • Kaiser MF; Myeloma Institute, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
  • Drayson MT; Leeds Institute of Cancer and Pathology, University of Leeds, UK.
  • Owen RG; Department of Haematology, The Royal Marsden Hospital NHS Foundation Trust, London, UK.
  • Jackson GH; The Institute of Cancer Research, London, UK.
  • Davies FE; Clinical Immunology, School of Immunity and Infection, University of Birmingham, UK.
  • Greaves M; Leeds Institute of Cancer and Pathology, University of Leeds, UK.
  • Morgan GJ; Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK.
Haematologica ; 104(7): 1440-1450, 2019 07.
Article en En | MEDLINE | ID: mdl-30733268
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Evolución Clonal / Mieloma Múltiple / Mutación / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Haematologica Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Italia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Biomarcadores de Tumor / Evolución Clonal / Mieloma Múltiple / Mutación / Recurrencia Local de Neoplasia Tipo de estudio: Clinical_trials / Diagnostic_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Female / Humans / Male Idioma: En Revista: Haematologica Año: 2019 Tipo del documento: Article País de afiliación: Reino Unido Pais de publicación: Italia